Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 20/20 | 0.54 |
| ▸ | MC3R | P41968 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | MC5R | P33032 | 6/20 | 0.49 |
| ▸ | MC1R | Q01726 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732908 | 1.00 | MC4R (0.54) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL733104 | 0.87 | MC4R (0.53) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL752025 | 0.87 | MC4R (0.53) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL733105 | 0.87 | MC4R (0.53) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL731793 | 0.83 | MC4R (0.54) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL731792 | 0.83 | MC4R (0.54) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL733761 | 0.82 | MC4R (0.69) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL733760 | 0.82 | MC4R (0.69) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL732507 | 0.81 | MC4R (0.52) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL732440 | 0.81 | MC4R (0.48) | MC4RMC3RKCNH2MC5RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989196-B1 | PIPERIDINOYLPYRROLIDINES AS MELANOCORTIN TYPE 4 RECEPTOR AGONISTS | PFIZER LTD (GB) | 2013-02-13 | — | — | EP | claimed |
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | claimed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | claimed |
| EP-1989196-B1 | PIPERIDINOYLPYRROLIDINES AS MELANOCORTIN TYPE 4 RECEPTOR AGONISTS | PFIZER LTD (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| EP-1989196-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | Pfizer Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007096763-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | PFIZER LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885KCNH2 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.